anurajms/meta_analysis huggingface dataset:
MESH terms:
Ketamine as an adjuvant to opioids for cancer pain
1. Analgesics [adverse effects, *therapeutic use]; 2. Analgesics, Opioid [*therapeutic use]; 3. Cancer Pain [*drug therapy]; 4. Chemotherapy, Adjuvant; 5. Hallucinations [chemically induced]; 6. Ketamine [adverse effects, *therapeutic use]; 7. Morphine [adverse effects, *therapeutic use]; 8. Palliative Care; 9. Randomized Controlled Trials as Topic;
MESH terms:
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer
1. Antibodies, Monoclonal [*therapeutic use]; 2. Antineoplastic Agents [*therapeutic use]; 3. Bevacizumab [therapeutic use]; 4. Colorectal Neoplasms [*drug therapy, genetics, mortality, pathology]; 5. Diarrhea [chemically induced, epidemiology]; 6. Disease-Free Survival; 7. ErbB Receptors [*antagonists & inhibitors]; 8. Exanthema [chemically induced, epidemiology]; 9. Neutropenia [chemically induced, epidemiology]; 10. Protein Kinase Inhibitors [*therapeutic use]; 11. Protein-Tyrosine Kinases [*antagonists & inhibitors]; 12. Proto-Oncogene Proteins p21(ras) [genetics]; 13. Quality of Life; 14. Randomized Controlled Trials as Topic;
MESH terms:
Platinum‐containing regimens for metastatic breast cancer
1. Alopecia [chemically induced, epidemiology]; 2. Anemia [chemically induced]; 3. Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; 4. Breast Neoplasms [*drug therapy, mortality, pathology]; 5. Carboplatin [administration & dosage, adverse effects]; 6. Cisplatin [administration & dosage, adverse effects]; 7. Disease-Free Survival; 8. Leukopenia [chemically induced, epidemiology]; 9. Nausea [chemically induced]; 10. Organoplatinum Compounds [administration & dosage, adverse effects]; 11. Pyridines [administration & dosage, adverse effects]; 12. Randomized Controlled Trials as Topic; 13. Survival Rate; 14. Triple Negative Breast Neoplasms [drug therapy, mortality, pathology]; 15. Vomiting [chemically induced, epidemiology];
MESH terms:
Early palliative care for adults with advanced cancer
1. *Palliative Care; 2. *Quality of Life; 3. Communication; 4. Neoplasms [pathology, *psychology, *therapy]; 5. Physician‐Patient Relations;
MESH terms:
Focal laser treatment in addition to chemotherapy for retinoblastoma
1. Combined Modality Therapy [methods]; 2. Laser Therapy [*methods]; 3. Retinal Neoplasms [*drug therapy, *surgery]; 4. Retinoblastoma [*drug therapy, *surgery];
MESH terms:
Empirical antibiotics targeting gram‐positive bacteria for the treatment of febrile neutropenic patients with cancer
1. Anti‐Bacterial Agents [adverse effects, *therapeutic use]; 2. Febrile Neutropenia [*drug therapy, mortality]; 3. Glycopeptides [adverse effects, therapeutic use]; 4. Gram‐Positive Bacterial Infections [*drug therapy, mortality]; 5. Neoplasms [*complications]; 6. Randomized Controlled Trials as Topic; 7. Treatment Failure;
MESH terms:
Drug therapy for symptoms associated with anxiety in adult palliative care patients
1. *Palliative Care; 2. Anti‐Anxiety Agents [*therapeutic use]; 3. Anxiety [*drug therapy]; 4. Terminally Ill [*psychology];
MESH terms:
Tramadol with or without paracetamol (acetaminophen) for cancer pain
1. Acetaminophen [adverse effects, *therapeutic use]; 2. Analgesics, Non‐Narcotic [adverse effects, *therapeutic use]; 3. Analgesics, Opioid [adverse effects, *therapeutic use]; 4. Cancer Pain [*drug therapy]; 5. Drug Therapy, Combination; 6. Randomized Controlled Trials as Topic; 7. Tramadol [adverse effects, *therapeutic use];
MESH terms:
Immunotherapy for metastatic renal cell carcinoma
1. Antineoplastic Agents [adverse effects, *therapeutic use]; 2. Bevacizumab [therapeutic use]; 3. Cancer Vaccines [therapeutic use]; 4. Carcinoma, Renal Cell [mortality, secondary, *therapy]; 5. Clinical Trials, Phase III as Topic; 6. Immunologic Factors [adverse effects, *therapeutic use]; 7. Immunotherapy [adverse effects, *methods]; 8. Indoles [therapeutic use]; 9. Interferon‐alpha [therapeutic use]; 10. Kidney Neoplasms [mortality, pathology, *therapy]; 11. Longevity [drug effects]; 12. Pyrroles [therapeutic use]; 13. Quality of Life; 14. Randomized Controlled Trials as Topic; 15. Sirolimus [analogs & derivatives, therapeutic use]; 16. Sunitinib;
MESH terms:
Partial nephrectomy versus radical nephrectomy for clinical localised renal masses
1. Carcinoma, Renal Cell [mortality, pathology, *surgery]; 2. Cause of Death; 3. Kidney Neoplasms [mortality, pathology, *surgery]; 4. Neoplasm Recurrence, Local [mortality]; 5. Nephrectomy [*methods, mortality]; 6. Randomized Controlled Trials as Topic; 7. Time Factors;
MESH terms:
Alvimopan for recovery of bowel function after radical cystectomy
1. *Recovery of Function; 2. Cardiovascular Diseases [etiology]; 3. Cystectomy [*adverse effects, methods]; 4. Defecation; 5. Eating; 6. Gastrointestinal Agents [adverse effects, *therapeutic use]; 7. Ileus [*drug therapy, etiology]; 8. Patient Discharge; 9. Patient Readmission; 10. Piperidines [adverse effects, *therapeutic use]; 11. Postoperative Complications [*drug therapy]; 12. Randomized Controlled Trials as Topic; 13. Time Factors; 14. Urinary Diversion [*adverse effects, methods];
MESH terms:
Biopsy versus resection for the management of low‐grade gliomas
1. Biopsy [methods]; 2. Brain [*pathology]; 3. Brain Neoplasms [*pathology, *surgery]; 4. Glioma [*pathology, *surgery];
MESH terms:
Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas
1. Antineoplastic Combined Chemotherapy Protocols [*administration & dosage, adverse effects]; 2. Hematopoietic Stem Cell Transplantation [*methods, mortality]; 3. Salvage Therapy [*methods, mortality]; 4. Sarcoma [*drug therapy, mortality]; 5. Transplantation, Autologous;
MESH terms:
Online support groups for women with breast cancer
1. Anxiety [therapy]; 2. Breast Neoplasms [*psychology]; 3. Consumer Health Information [*statistics & numerical data]; 4. Depression [therapy]; 5. Peer Group; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Self‐Help Groups [*statistics & numerical data]; 9. Time Factors;
MESH terms:
Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating non‐muscle‐invasive bladder cancer
1. Adjuvants, Immunologic [*administration & dosage, adverse effects]; 2. Administration, Intravesical; 3. Antineoplastic Agents [*administration & dosage, adverse effects]; 4. BCG Vaccine; 5. Carcinoma in Situ [mortality, pathology, *therapy]; 6. Combined Modality Therapy [adverse effects, methods]; 7. Disease Progression; 8. Drug Administration Schedule; 9. Interferon-alpha [*administration & dosage, adverse effects]; 10. Neoplasm Recurrence, Local; 11. Randomized Controlled Trials as Topic; 12. Time Factors; 13. Urinary Bladder Neoplasms [mortality, pathology, *therapy]; 14. Withholding Treatment [statistics & numerical data];
MESH terms:
External beam radiotherapy for unresectable hepatocellular carcinoma
1. Alanine Transaminase [blood]; 2. Bilirubin [blood]; 3. Carcinoma, Hepatocellular [enzymology, pathology, *radiotherapy]; 4. Cause of Death; 5. Chemoembolization, Therapeutic [mortality]; 6. Combined Modality Therapy [methods, mortality]; 7. Liver Neoplasms [enzymology, pathology, *radiotherapy]; 8. Radiotherapy [methods, mortality]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for raising breast cancer awareness in women
1. *Awareness; 2. *Health Knowledge, Attitudes, Practice; 3. *Pamphlets; 4. Age Factors; 5. Breast Neoplasms [*diagnosis]; 6. Breast Self‐Examination [statistics & numerical data]; 7. Health Education [*methods, statistics & numerical data]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Methadone for cancer pain
1. Analgesics, Opioid [*therapeutic use]; 2. Methadone [*therapeutic use]; 3. Morphine [therapeutic use]; 4. Neoplasms [*complications]; 5. Pain [*drug therapy, etiology]; 6. Pain Measurement; 7. Randomized Controlled Trials as Topic;
MESH terms:
Second‐line systemic therapy for metastatic colorectal cancer
1. Antineoplastic Agents [*therapeutic use]; 2. Antineoplastic Combined Chemotherapy Protocols [administration & dosage, *therapeutic use]; 3. Bevacizumab [administration & dosage]; 4. Camptothecin [administration & dosage, analogs & derivatives, therapeutic use]; 5. Colorectal Neoplasms [*drug therapy, mortality, pathology]; 6. Fluorouracil [administration & dosage]; 7. Irinotecan; 8. Leucovorin [administration & dosage]; 9. Organoplatinum Compounds [administration & dosage]; 10. Randomized Controlled Trials as Topic; 11. Survival Rate;
MESH terms:
Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
1. Colposcopy [*statistics & numerical data]; 2. Papillomaviridae [isolation & purification]; 3. Patient Compliance [statistics & numerical data]; 4. Precancerous Conditions [*diagnosis, *pathology]; 5. Randomized Controlled Trials as Topic; 6. *Referral and Consultation; 7. Time Factors; 8. Uterine Cervical Dysplasia [*diagnosis, *pathology]; 9. Vaginal Smears [*statistics & numerical data]; 10. Watchful Waiting;
MESH terms:
Antibiotics for infection prevention after excision of the cervical transformation zone
1. Anti-Bacterial Agents [adverse effects, *therapeutic use]; 2. Bacterial Infections [*prevention & control]; 3. Postoperative Complications [*prevention & control]; 4. Postoperative Hemorrhage [etiology]; 5. Precancerous Conditions [*surgery]; 6. Randomized Controlled Trials as Topic; 7. Uterine Cervical Dysplasia [*surgery]; 8. Uterine Cervical Neoplasms [*surgery];
MESH terms:
Dietary fibre for the prevention of recurrent colorectal adenomas and carcinomas
1. Adenoma [*prevention & control]; 2. Adenomatous Polyps [*prevention & control]; 3. Colorectal Neoplasms [*prevention & control]; 4. Dietary Fiber [adverse effects, *therapeutic use]; 5. Neoplasm Recurrence, Local; 6. Randomized Controlled Trials as Topic;
MESH terms:
Axillary treatment for operable primary breast cancer
1. Axilla; 2. Breast Neoplasms [mortality, radiotherapy, *surgery]; 3. Lymph Node Excision [adverse effects, *methods]; 4. Lymphedema [etiology]; 5. Neoplasm Recurrence, Local [mortality]; 6. Randomized Controlled Trials as Topic; 7. Sentinel Lymph Node Biopsy [adverse effects, methods];
MESH terms:
Fulvestrant for hormone‐sensitive metastatic breast cancer
1. Anastrozole; 2. Antineoplastic Agents, Hormonal [adverse effects, *therapeutic use]; 3. Breast Neoplasms [*drug therapy, mortality, pathology]; 4. Disease‐Free Survival; 5. Estradiol [adverse effects, *analogs & derivatives, therapeutic use]; 6. Fulvestrant; 7. Neoplasms, Hormone‐Dependent [drug therapy]; 8. Nitriles [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Triazoles [therapeutic use];
MESH terms:
Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women diagnosed with breast cancer
1. *Mental Health; 2. *Quality of Life; 3. *Yoga; 4. Anxiety [etiology, therapy]; 5. Breast Neoplasms [*complications, *psychology, therapy]; 6. Depression [etiology, therapy]; 7. Fatigue [etiology, therapy]; 8. Randomized Controlled Trials as Topic; 9. Sleep Wake Disorders [etiology, therapy];
MESH terms:
Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small‐volume primary oropharyngeal carcinoma
1. *Chemoradiotherapy, Adjuvant; 2. *Robotic Surgical Procedures; 3. Carcinoma, Squamous Cell [radiotherapy, surgery, *therapy]; 4. Laser Therapy [*methods]; 5. Microsurgery [*methods]; 6. Oropharyngeal Neoplasms [pathology, radiotherapy, surgery, *therapy]; 7. Radiotherapy, Adjuvant;
MESH terms:
Nipple‐ and areola‐sparing mastectomy for the treatment of breast cancer
1. *Nipples; 2. Breast Neoplasms [mortality, *surgery]; 3. Carcinoma, Intraductal, Noninfiltrating [mortality, *surgery]; 4. Cohort Studies; 5. Mastectomy [adverse effects, *methods, mortality]; 6. Neoplasm Recurrence, Local; 7. Organ Sparing Treatments [adverse effects, *methods]; 8. Postoperative Complications; 9. Skin;
MESH terms:
Educational interventions for the management of cancer‐related fatigue in adults
1. Activities of Daily Living; 2. Anxiety [therapy]; 3. Fatigue [*etiology, *therapy]; 4. Neoplasms [*complications, therapy]; 5. Patient Education as Topic [*methods]; 6. Problem Solving; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Reinforcement, Psychology;
MESH terms:
Adjuvant platinum‐based chemotherapy for early stage cervical cancer
1. Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; 2. Chemotherapy, Adjuvant [methods]; 3. Cisplatin [administration & dosage]; 4. Fluorouracil [administration & dosage]; 5. Hysterectomy; 6. Neoplasm Staging; 7. Platinum Compounds [*therapeutic use]; 8. Radiotherapy, Adjuvant; 9. Randomized Controlled Trials as Topic; 10. Survival Analysis; 11. Uterine Cervical Neoplasms [*drug therapy, pathology, radiotherapy, surgery];
MESH terms:
Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults
1. Benzodiazepines [adverse effects, *therapeutic use]; 2. Dyspnea [*drug therapy, etiology]; 3. Lung Neoplasms [*complications]; 4. Pulmonary Disease, Chronic Obstructive [*complications]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease
1. Chronic Disease; 2. Disease Progression; 3. Heart Failure [complications]; 4. Leg; 5. Muscle Strength; 6. Muscle Weakness [etiology, *therapy]; 7. Muscle, Skeletal [anatomy & histology]; 8. Physical Exertion [physiology]; 9. Pulmonary Disease, Chronic Obstructive [complications]; 10. Quadriceps Muscle [physiology]; 11. Randomized Controlled Trials as Topic; 12. Respiration Disorders [complications]; 13. Thoracic Neoplasms [complications]; 14. Transcutaneous Electric Nerve Stimulation [adverse effects, *methods];
MESH terms:
Laparoscopy versus laparotomy for FIGO stage I ovarian cancer
1. Early Detection of Cancer [*methods]; 2. *Laparoscopy; 3. *Laparotomy; 4. Neoplasm Staging; 5. Ovarian Neoplasms [pathology, *surgery];
MESH terms:
Exercise for women receiving adjuvant therapy for breast cancer
1. *Exercise Therapy; 2. Breast Neoplasms [psychology, *therapy]; 3. Chemotherapy, Adjuvant [adverse effects]; 4. Cognition; 5. Depression [therapy]; 6. Fatigue [rehabilitation]; 7. Lymphedema [etiology]; 8. Physical Fitness; 9. Quality of Life; 10. Radiotherapy, Adjuvant [adverse effects]; 11. Randomized Controlled Trials as Topic; 12. Weight Gain;
MESH terms:
Therapeutic exercises for affecting post‐treatment swallowing in people treated for advanced‐stage head and neck cancers
1. *Deglutition; 2. *Myofunctional Therapy; 3. Chemoradiotherapy; 4. Deglutition Disorders [etiology, *therapy]; 5. Head and Neck Neoplasms [pathology, *therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Nutritional interventions for survivors of childhood cancer
1. Bone Density; 2. Calcium, Dietary [*administration & dosage]; 3. Cardiovascular Diseases [prevention & control]; 4. Endocrine System Diseases [prevention & control]; 5. Fast Foods; 6. *Health Behavior; 7. Intention to Treat Analysis; 8. Metabolic Syndrome [prevention & control]; 9. Milk; 10. *Neoplasms [therapy]; 11. Nutrition Therapy [*methods]; 12. Osteoporosis [prevention & control]; 13. Precursor Cell Lymphoblastic Leukemia-Lymphoma [therapy]; 14. Randomized Controlled Trials as Topic; 15. *Survivors; 16. Vitamin D [*administration & dosage]; 17. Vitamins [*administration & dosage];
MESH terms:
Non‐pharmacological interventions for cognitive impairment due to systemic cancer treatment
1. Breast Neoplasms [*therapy]; 2. Cognition [physiology]; 3. Cognition Disorders [etiology, *therapy]; 4. Exercise; 5. Meditation [methods]; 6. Memory; 7. Mental Health; 8. Neoplasms [therapy]; 9. Randomized Controlled Trials as Topic; 10. Survivors; 11. Therapy, Computer-Assisted [methods];
MESH terms:
Interventions for treating oral leukoplakia to prevent oral cancer
1. Leukoplakia, Oral [*therapy]; 2. Mouth Neoplasms [*prevention & control]; 3. Randomized Controlled Trials as Topic;
MESH terms:
Sun protection for preventing basal cell and squamous cell skin cancers
1. Australia; 2. Carcinoma, Basal Cell [*prevention & control]; 3. Carcinoma, Squamous Cell [*prevention & control]; 4. Neoplasms, Radiation‐Induced [*prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Skin Neoplasms [*prevention & control]; 7. Sunlight [*adverse effects]; 8. Sunscreening Agents [*administration & dosage, adverse effects]; 9. Ultraviolet Rays [adverse effects]; 10. Vitamins [administration & dosage, adverse effects]; 11. beta Carotene [administration & dosage, adverse effects];
MESH terms:
Molecular‐targeted first‐line therapy for advanced gastric cancer
1. Adenocarcinoma [*drug therapy, mortality, pathology]; 2. Angiogenesis Inhibitors [therapeutic use]; 3. Disease-Free Survival; 4. ErbB Receptors [antagonists & inhibitors]; 5. Esophageal Neoplasms [*drug therapy, mortality, pathology]; 6. *Esophagogastric Junction; 7. Molecular Targeted Therapy [adverse effects, *methods]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Receptor, ErbB-2 [antagonists & inhibitors]; 11. Stomach Neoplasms [*drug therapy, mortality, pathology];
MESH terms:
Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
1. Administration, Oral; 2. Analgesics [*administration & dosage]; 3. Colposcopy [*adverse effects]; 4. Drug Therapy, Combination [methods]; 5. Intraoperative Complications [*therapy]; 6. Pain Management [*methods]; 7. Pain Measurement; 8. Pain, Postoperative [*therapy]; 9. Randomized Controlled Trials as Topic; 10. Transcutaneous Electric Nerve Stimulation [methods]; 11. Uterine Cervical Dysplasia [*surgery]; 12. Uterine Cervical Neoplasms [*surgery];
MESH terms:
Hypofractionated radiation therapy for early breast cancer
1. *Radiation Dose Hypofractionation; 2. Breast Neoplasms [*radiotherapy, surgery]; 3. Combined Modality Therapy [methods]; 4. Dose Fractionation, Radiation; 5. Mastectomy, Segmental; 6. Radiation Injuries [complications, mortality]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Intracystic bleomycin for cystic craniopharyngiomas in children
1. Antibiotics, Antineoplastic [*administration & dosage]; 2. Bleomycin [*administration & dosage]; 3. Craniopharyngioma [*drug therapy]; 4. Cysts [*drug therapy]; 5. Injections, Intralesional [methods]; 6. Phosphorus Radioisotopes [administration & dosage]; 7. Pituitary Neoplasms [*drug therapy]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer
1. Antineoplastic Agents, Alkylating [*therapeutic use]; 2. Antineoplastic Agents, Hormonal [*therapeutic use]; 3. Busulfan [*analogs & derivatives, therapeutic use]; 4. Carcinoma, Ovarian Epithelial; 5. Gonadotropin-Releasing Hormone [*agonists]; 6. Leuprolide [*therapeutic use]; 7. Neoplasm Recurrence, Local [*drug therapy]; 8. Neoplasms, Glandular and Epithelial [*drug therapy]; 9. Ovarian Neoplasms [*drug therapy]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Radiotherapy for diffuse brainstem glioma in children and young adults
1. *Brain Stem; 2. *Dose Fractionation, Radiation; 3. Brain Neoplasms [mortality, pathology, *radiotherapy]; 4. Glioma [mortality, pathology, *radiotherapy]; 5. Neoplasm Invasiveness; 6. Randomized Controlled Trials as Topic;
MESH terms:
Massage with or without aromatherapy for symptom relief in people with cancer
1. *Aromatherapy; 2. Affect; 3. Anxiety [*therapy]; 4. Breast Neoplasms [complications]; 5. Depression [*therapy]; 6. Fatigue [therapy]; 7. Massage [*methods]; 8. Neoplasms [*complications, psychology]; 9. Pain Management [*methods]; 10. Plant Oils [therapeutic use];
MESH terms:
Follow‐up strategies for women treated for early breast cancer
1. Breast Neoplasms [*diagnosis, mortality, pathology, *therapy]; 2. Follow‐Up Studies; 3. General Practice; 4. Mammography; 5. Medical Oncology; 6. Neoplasm Recurrence, Local [*diagnosis, mortality]; 7. Neoplasm Staging; 8. Physical Examination; 9. Quality of Life; 10. Randomized Controlled Trials as Topic;
MESH terms:
High‐dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer
1. *Bone Marrow Transplantation; 2. *Stem Cell Transplantation; 3. Antineoplastic Agents [*administration & dosage, adverse effects]; 4. Antineoplastic Combined Chemotherapy Protocols [*administration & dosage, adverse effects]; 5. Breast Neoplasms [*drug therapy, mortality, *surgery]; 6. Combined Modality Therapy [methods]; 7. Prognosis; 8. Randomized Controlled Trials as Topic; 9. Salvage Therapy; 10. Survival Rate; 11. Time Factors; 12. Transplantation, Autologous;
MESH terms:
Different types of implants for reconstructive breast surgery
1. *Mammaplasty; 2. Breast Implants [*classification]; 3. Breast Neoplasms [*surgery]; 4. Hydrogels; 5. Mastectomy; 6. Patient Satisfaction; 7. Prophylactic Surgical Procedures; 8. Prosthesis Failure; 9. Randomized Controlled Trials as Topic; 10. Silicone Gels; 11. Sodium Chloride;
MESH terms:
Stents for the prevention of pancreatic fistula following pancreaticoduodenectomy
1. Hospital Mortality; 2. Pancreatic Fistula [*prevention & control]; 3. Pancreaticoduodenectomy [*adverse effects]; 4. Randomized Controlled Trials as Topic; 5. Reoperation; 6. Stents [*classification]; 7. Time Factors; 8. Treatment Outcome;
MESH terms:
Non‐surgical interventions for late rectal problems (proctopathy) of radiotherapy in people who have received radiotherapy to the pelvis
1. Anti‐Inflammatory Agents [therapeutic use]; 2. Electrocoagulation [methods]; 3. Fatty Acids [therapeutic use]; 4. Formaldehyde [therapeutic use]; 5. Hyperbaric Oxygenation; 6. Pelvic Neoplasms [radiotherapy]; 7. Proctitis [*therapy]; 8. Radiation Injuries [*therapy]; 9. Randomized Controlled Trials as Topic; 10. Rectum [*radiation effects]; 11. Sucralfate [therapeutic use];
MESH terms:
Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia
1. Anti-Bacterial Agents [therapeutic use]; 2. Antifungal Agents [therapeutic use]; 3. Antineoplastic Agents [*adverse effects]; 4. Bacterial Infections [*prevention & control]; 5. Fever [diet therapy]; 6. Mycoses [*prevention & control]; 7. Neoplasms [*drug therapy]; 8. Neutropenia [chemically induced, *diet therapy]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Oral morphine for cancer pain
1. Administration, Oral; 2. Analgesics, Opioid [*administration & dosage]; 3. Morphine [*administration & dosage]; 4. Neoplasms [*complications]; 5. Pain [*drug therapy, radiotherapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Chromoscopy versus conventional endoscopy for the detection of polyps in the colon and rectum
1. *Indicators and Reagents; 2. *Indigo Carmine; 3. Colonic Polyps [diagnosis]; 4. Colonoscopy [*methods]; 5. Intestinal Polyps [*diagnosis]; 6. Precancerous Conditions [diagnosis]; 7. Randomized Controlled Trials as Topic; 8. Rectal Diseases [*diagnosis];
MESH terms:
Ganoderma lucidum (Reishi mushroom) for cancer treatment
1. Antineoplastic Agents [immunology, *therapeutic use]; 2. Immunity, Cellular [immunology]; 3. Neoplasms [*drug therapy, immunology, therapy]; 4. Randomized Controlled Trials as Topic; 5. Reishi [*chemistry];
MESH terms:
Laparoscopic versus open distal pancreatectomy for pancreatic cancer
1. *Laparoscopy [adverse effects, mortality]; 2. Case‐Control Studies; 3. Pancreatectomy [adverse effects, *methods, mortality]; 4. Pancreatic Neoplasms [*surgery]; 5. Retrospective Studies;
MESH terms:
Laparoscopic versus open gastrectomy for gastric cancer
1. Gastrectomy [adverse effects, *methods, mortality]; 2. Laparoscopy [adverse effects, *methods, mortality]; 3. Stomach Neoplasms [mortality, *surgery];
MESH terms:
Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness
1. Analgesics, Opioid [adverse effects, *therapeutic use]; 2. Dyspnea [*drug therapy]; 3. Exercise Tolerance; 4. Morphine [adverse effects, therapeutic use]; 5. Palliative Care [*methods]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Terminal Care [*methods]; 9. Time Factors; 10. Walking;
MESH terms:
Laparoscopic versus open transhiatal oesophagectomy for oesophageal cancer
1. Adenocarcinoma [*surgery]; 2. Carcinoma, Squamous Cell [*surgery]; 3. Diaphragm; 4. Esophageal Neoplasms [*surgery]; 5. Esophagectomy [adverse effects, *methods]; 6. Laparoscopy [*methods]; 7. Retrospective Studies;
MESH terms:
Physical exercise training interventions for children and young adults during and after treatment for childhood cancer
1. *Exercise; 2. *Physical Fitness; 3. Antineoplastic Agents [therapeutic use]; 4. Body Mass Index; 5. Bone Density; 6. Controlled Clinical Trials as Topic; 7. Muscle Strength [physiology]; 8. Muscle, Skeletal [physiology]; 9. Neoplasms [therapy]; 10. Physical Endurance [physiology]; 11. Precursor Cell Lymphoblastic Leukemia‐Lymphoma [*drug therapy]; 12. Quality of Life; 13. Randomized Controlled Trials as Topic; 14. Range of Motion, Articular [physiology];
MESH terms:
Non‐surgical versus surgical treatment for oesophageal cancer
1. *Chemoradiotherapy [mortality]; 2. Esophageal Neoplasms [mortality, *therapy]; 3. Health Status; 4. Quality of Life; 5. Radiotherapy [mortality]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Very early discharge versus early discharge versus non‐early discharge in children with cancer and febrile neutropenia
1. Anti-Bacterial Agents [therapeutic use]; 2. Febrile Neutropenia [*chemically induced]; 3. *Length of Stay; 4. Neoplasms [*drug therapy]; 5. *Patient Discharge; 6. Randomized Controlled Trials as Topic; 7. *Standard of Care; 8. Time Factors;
MESH terms:
Pylorus‐preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma
1. *Pylorus; 2. Ampulla of Vater [*surgery]; 3. Blood Loss, Surgical; 4. Common Bile Duct Neoplasms [mortality, *surgery]; 5. Gastric Emptying; 6. Operative Time; 7. Organ Sparing Treatments [*methods]; 8. Pancreatic Fistula [etiology]; 9. Pancreatic Neoplasms [mortality, *surgery]; 10. Pancreaticoduodenectomy [adverse effects, *methods, mortality]; 11. Quality of Life; 12. Randomized Controlled Trials as Topic;
MESH terms:
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer
1. Alopecia [chemically induced]; 2. Antimetabolites, Antineoplastic [adverse effects, therapeutic use]; 3. Antineoplastic Agents, Phytogenic [adverse effects, therapeutic use]; 4. Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; 5. Camptothecin [administration & dosage, adverse effects, analogs & derivatives]; 6. Colorectal Neoplasms [*drug therapy, mortality, pathology]; 7. Diarrhea [chemically induced]; 8. Disease-Free Survival; 9. Fluorouracil [administration & dosage, adverse effects]; 10. Irinotecan; 11. Nausea [chemically induced]; 12. Neutropenia; 13. Quality of Life; 14. Randomized Controlled Trials as Topic;
MESH terms:
End‐of‐life care pathways for improving outcomes in caring for the dying
1. *Critical Pathways; 2. *Terminal Care [psychology]; 3. Dyspnea [prevention & control]; 4. Nausea [prevention & control]; 5. Pain Management; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Treatment Outcome; 9. Vomiting [prevention & control];
MESH terms:
Percutaneous endoscopic gastrostomy versus percutaneous radiological gastrostomy for swallowing disturbances
1. Deglutition Disorders [*complications]; 2. Enteral Nutrition [*methods]; 3. Gastrostomy [*methods];
MESH terms:
Antiemetic medication for prevention and treatment of chemotherapy‐induced nausea and vomiting in childhood
1. Antiemetics [adverse effects, *therapeutic use]; 2. Antineoplastic Agents [*adverse effects]; 3. Dexamethasone [therapeutic use]; 4. Drug Therapy, Combination [adverse effects, methods]; 5. Nausea [chemically induced, *drug therapy, *prevention & control]; 6. Neoplasms [drug therapy]; 7. Randomized Controlled Trials as Topic; 8. Serotonin Antagonists [adverse effects, therapeutic use]; 9. Vomiting [chemically induced, *drug therapy, *prevention & control];
MESH terms:
Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer
1. Antifibrinolytic Agents [*therapeutic use]; 2. Blood Loss, Surgical [*prevention & control, statistics & numerical data]; 3. Blood Transfusion [statistics & numerical data]; 4. Cytoreduction Surgical Procedures [adverse effects, *methods]; 5. Erythrocyte Transfusion [*statistics & numerical data]; 6. Incidence; 7. Ovarian Neoplasms [pathology, *surgery]; 8. Patient Readmission [statistics & numerical data]; 9. Plasma; 10. Randomized Controlled Trials as Topic; 11. Reoperation [statistics & numerical data]; 12. Thromboembolism [epidemiology]; 13. Tranexamic Acid [*therapeutic use];
MESH terms:
Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia
1. *Drug Resistance, Neoplasm; 2. Gestational Trophoblastic Disease [*drug therapy]; 3. Neoplasm Recurrence, Local [*drug therapy];
MESH terms:
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
1. Antineoplastic Agents [*administration & dosage, adverse effects]; 2. Disease-Free Survival; 3. Induction Chemotherapy [adverse effects, *methods]; 4. Infusions, Intravenous; 5. Infusions, Parenteral [adverse effects, *methods]; 6. Ovarian Neoplasms [*drug therapy, mortality]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Interval debulking surgery for advanced epithelial ovarian cancer
1. Antineoplastic Agents [*therapeutic use]; 2. Chemotherapy, Adjuvant [mortality]; 3. Combined Modality Therapy [methods]; 4. Induction Chemotherapy [mortality]; 5. Neoadjuvant Therapy [methods, mortality]; 6. Ovarian Neoplasms [*drug therapy, mortality, pathology, *surgery]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Survival Rate; 10. Tumor Burden [drug effects];
MESH terms:
Localization techniques for guided surgical excision of non‐palpable breast lesions
1. *Fiducial Markers; 2. Breast Neoplasms [*diagnosis, pathology, *surgery]; 3. Iodine Radioisotopes; 4. Palpation; 5. Randomized Controlled Trials as Topic; 6. Tumor Burden;
MESH terms:
Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer
1. Antineoplastic Agents [*therapeutic use]; 2. Carboplatin [therapeutic use]; 3. Chemotherapy, Adjuvant [methods]; 4. Cisplatin [therapeutic use]; 5. Disease‐Free Survival; 6. Early Detection of Cancer; 7. Melphalan [therapeutic use]; 8. Neoplasm Staging; 9. Ovarian Neoplasms [*drug therapy, pathology, surgery]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy
1. Antibodies, Monoclonal, Humanized [therapeutic use]; 2. Antineoplastic Agents [*therapeutic use]; 3. Carcinoma, Squamous Cell [mortality, *therapy]; 4. Cetuximab [therapeutic use]; 5. Cisplatin [therapeutic use]; 6. Docetaxel; 7. ErbB Receptors; 8. Gefitinib; 9. Immunotherapy [adverse effects, *methods]; 10. Lapatinib; 11. Molecular Targeted Therapy [adverse effects, *methods]; 12. Mouth Neoplasms [mortality, *therapy]; 13. Oropharyngeal Neoplasms [mortality, *therapy]; 14. Protein Kinase Inhibitors [therapeutic use]; 15. Protein‐Tyrosine Kinases [antagonists & inhibitors]; 16. Quinazolines [therapeutic use]; 17. Randomized Controlled Trials as Topic; 18. Taxoids [therapeutic use];
MESH terms:
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
1. Antiemetics [adverse effects, *therapeutic use]; 2. Antineoplastic Agents [adverse effects]; 3. Cannabinoids [adverse effects, *therapeutic use]; 4. Chlorpromazine [adverse effects, therapeutic use]; 5. Dizziness [chemically induced]; 6. Domperidone [adverse effects, therapeutic use]; 7. Euphoria; 8. Metoclopramide [adverse effects, therapeutic use]; 9. Nausea [chemically induced, *drug therapy]; 10. Neoplasms [*drug therapy]; 11. Prochlorperazine [adverse effects, therapeutic use]; 12. Randomized Controlled Trials as Topic; 13. Vomiting [chemically induced, *drug therapy];
MESH terms:
Stapler versus scalpel resection followed by hand‐sewn closure of the pancreatic remnant for distal pancreatectomy
1. *Surgical Instruments; 2. *Surgical Staplers; 3. *Suture Techniques; 4. Fibrin Tissue Adhesive; 5. Operative Time; 6. Pancreas [*surgery]; 7. Pancreatectomy [adverse effects, *methods, mortality]; 8. Pancreatic Fistula [epidemiology, etiology]; 9. Randomized Controlled Trials as Topic; 10. Surgical Mesh;
MESH terms:
Levomepromazine for nausea and vomiting in palliative care
1. *Palliative Care; 2. Antiemetics [adverse effects, *therapeutic use]; 3. Methotrimeprazine [adverse effects, *therapeutic use]; 4. Nausea [*drug therapy]; 5. Vomiting [*drug therapy];
MESH terms:
Haloperidol for the treatment of nausea and vomiting in palliative care patients
1. Antiemetics [*therapeutic use]; 2. Diphenhydramine [therapeutic use]; 3. Gels; 4. Haloperidol [*therapeutic use]; 5. Lorazepam [therapeutic use]; 6. Nausea [*drug therapy]; 7. *Palliative Care; 8. Randomized Controlled Trials as Topic; 9. Vomiting [*drug therapy];
MESH terms:
Chemotherapy for advanced non‐small cell lung cancer in the elderly population
1. Antineoplastic Agents [adverse effects, *therapeutic use]; 2. Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; 3. Carboplatin [therapeutic use]; 4. Carcinoma, Non‐Small‐Cell Lung [*drug therapy, mortality, pathology]; 5. Cisplatin [therapeutic use]; 6. Lung Neoplasms [*drug therapy, mortality, pathology]; 7. Platinum Compounds [*therapeutic use]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic;
MESH terms:
Acupuncture for cancer pain in adults
1. Acupuncture Therapy [*methods]; 2. Acupuncture, Ear [methods]; 3. Neoplasms [*complications]; 4. Pain [etiology]; 5. Pain Management [*methods]; 6. Pain Measurement; 7. Randomized Controlled Trials as Topic;
MESH terms:
High‐dose chemotherapy and autologous haematopoietic stem cell rescue for children with high‐risk neuroblastoma
1. Age Factors; 2. Antineoplastic Combined Chemotherapy Protocols [*administration & dosage, adverse effects]; 3. Bone Marrow [drug effects]; 4. Disease‐Free Survival; 5. Hematopoietic Stem Cell Transplantation [*methods, mortality]; 6. Neoplasm Recurrence, Local; 7. Neuroblastoma [mortality, *therapy]; 8. Prognosis; 9. Randomized Controlled Trials as Topic; 10. Salvage Therapy [methods];
MESH terms:
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients
1. Antineoplastic Agents, Alkylating [*therapeutic use]; 2. Bone Neoplasms [*drug therapy]; 3. Cyclophosphamide [*therapeutic use]; 4. Ifosfamide [*therapeutic use]; 5. Sarcoma [*drug therapy]; 6. Soft Tissue Neoplasms [*drug therapy];
MESH terms:
Oral tapentadol for cancer pain
1. Neoplasms [*complications]; 2. Pain [*drug therapy]; 3. Phenols [*therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Receptors, Opioid, mu [*therapeutic use]; 6. Tapentadol;
MESH terms:
Nutritional support in children and young people with cancer undergoing chemotherapy
1. Enteral Nutrition [*methods]; 2. Leukemia [drug therapy]; 3. Malnutrition [etiology, *therapy]; 4. Neoplasms [*drug therapy]; 5. Parenteral Nutrition [*methods]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Multidisciplinary rehabilitation after primary brain tumour treatment
1. Anal Canal; 2. Brain Neoplasms [*rehabilitation, therapy]; 3. Combined Modality Therapy [methods]; 4. Controlled Clinical Trials as Topic; 5. Locomotion; 6. Quality of Life; 7. Social Participation;
MESH terms:
Spinal cord stimulation for cancer‐related pain in adults
1. *Spinal Cord Stimulation [adverse effects]; 2. Analgesics, Opioid [administration & dosage]; 3. Cerebrospinal Fluid Leak [etiology]; 4. Checklist; 5. Controlled Before‐After Studies; 6. Neoplasms [*complications]; 7. Pain [*etiology]; 8. Pain Management [adverse effects, *methods]; 9. Pain Measurement;
MESH terms:
Taxane‐containing regimens for metastatic breast cancer
1. Antineoplastic Agents, Hormonal [*therapeutic use]; 2. Antineoplastic Agents, Phytogenic [*therapeutic use]; 3. Breast Neoplasms [*drug therapy, mortality, pathology]; 4. Bridged‐Ring Compounds [therapeutic use]; 5. Disease Progression; 6. Paclitaxel [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Tamoxifen [therapeutic use]; 9. Taxoids [*therapeutic use];
MESH terms:
Pharmacological treatments for fatigue associated with palliative care
1. Amantadine [therapeutic use]; 2. Benzhydryl Compounds [therapeutic use]; 3. Carnitine [therapeutic use]; 4. Central Nervous System Stimulants [therapeutic use]; 5. Chronic Disease; 6. Fatigue [*drug therapy, etiology]; 7. Kidney Failure, Chronic [complications]; 8. Methylphenidate [therapeutic use]; 9. Modafinil; 10. Multiple Sclerosis [complications]; 11. Neoplasms [complications]; 12. *Palliative Care; 13. Pemoline [therapeutic use]; 14. Randomized Controlled Trials as Topic;
MESH terms:
Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances
1. Deglutition Disorders [*complications]; 2. Enteral Nutrition [*methods, mortality]; 3. Gastrostomy [adverse effects, *methods, mortality]; 4. Intubation, Gastrointestinal [adverse effects, methods, mortality]; 5. Malnutrition [etiology, *therapy]; 6. Pneumonia [etiology]; 7. Randomized Controlled Trials as Topic; 8. Treatment Failure;
MESH terms:
Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma
1. Antineoplastic Combined Chemotherapy Protocols [administration & dosage, adverse effects, *therapeutic use]; 2. Carboplatin [administration & dosage, adverse effects]; 3. Cisplatin [administration & dosage, adverse effects]; 4. Cyclophosphamide [administration & dosage, adverse effects]; 5. Drug Administration Schedule; 6. Etoposide [administration & dosage, adverse effects]; 7. Induction Chemotherapy [adverse effects, *methods]; 8. Neuroblastoma [*drug therapy]; 9. Randomized Controlled Trials as Topic; 10. Vincristine [administration & dosage, adverse effects];
MESH terms:
Interventions for cough in cancer
1. Antitussive Agents [therapeutic use]; 2. Brachytherapy [methods]; 3. Cough [etiology, *therapy]; 4. Drugs, Chinese Herbal [therapeutic use]; 5. Laser Therapy [methods]; 6. Neoplasms [*complications, therapy]; 7. Photochemotherapy [methods]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma
1. Disease-Free Survival; 2. *Lymph Node Excision; 3. Melanoma [mortality, *pathology, *surgery]; 4. Melanoma, Cutaneous Malignant; 5. Randomized Controlled Trials as Topic; 6. *Sentinel Lymph Node Biopsy; 7. Skin Neoplasms [mortality, *pathology, *surgery]; 8. Survival Rate; 9. Watchful Waiting;
MESH terms:
Laxatives for the management of constipation in people receiving palliative care
1. Analgesics, Opioid [adverse effects]; 2. Anthraquinones [therapeutic use]; 3. Cathartics [adverse effects, *therapeutic use]; 4. Constipation [chemically induced, *drug therapy]; 5. Lactulose [therapeutic use]; 6. Magnesium Hydroxide [therapeutic use]; 7. Naltrexone [adverse effects, *analogs & derivatives, therapeutic use]; 8. *Palliative Care; 9. Paraffin [therapeutic use]; 10. Quaternary Ammonium Compounds [adverse effects, therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Senna Extract [therapeutic use];
MESH terms:
Laetrile treatment for cancer
1. Amygdalin [adverse effects, *therapeutic use]; 2. Antineoplastic Agents, Phytogenic [adverse effects, *therapeutic use]; 3. Neoplasms [*drug therapy];
MESH terms:
Buprenorphine for treating cancer pain
1. Administration, Cutaneous; 2. Administration, Oral; 3. Administration, Sublingual; 4. Analgesics, Opioid [administration & dosage, *therapeutic use]; 5. Buprenorphine [administration & dosage, *therapeutic use]; 6. Neoplasms [*complications]; 7. Pain [*drug therapy, etiology]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Chewing gum for postoperative recovery of gastrointestinal function
1. *Chewing Gum; 2. Abdomen [surgery]; 3. Gastrointestinal Motility [*physiology]; 4. Ileus [*therapy]; 5. Length of Stay; 6. Postoperative Complications [*therapy]; 7. Postoperative Period; 8. Randomized Controlled Trials as Topic; 9. Recovery of Function [*physiology]; 10. Time Factors;
MESH terms:
Conservative interventions for preventing clinically detectable upper‐limb lymphoedema in patients who are at risk of developing lymphoedema after breast cancer therapy
1. *Patient Education as Topic; 2. Breast Neoplasms [*therapy]; 3. Drainage [*methods]; 4. Exercise Therapy [*methods]; 5. Lymphedema [*prevention & control]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Range of Motion, Articular; 9. Resistance Training [*methods]; 10. Shoulder Joint [physiopathology];
MESH terms:
Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma
1. Acetic Acid [*administration & dosage, adverse effects]; 2. Administration, Cutaneous; 3. Antineoplastic Agents [*administration & dosage, adverse effects]; 4. Carcinoma, Hepatocellular [*drug therapy, pathology, surgery]; 5. Catheter Ablation [methods]; 6. Ethanol [*administration & dosage, adverse effects]; 7. Liver Neoplasms [*drug therapy, pathology, surgery]; 8. Randomized Controlled Trials as Topic; 9. Tumor Burden;
MESH terms:
Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer
1. *Palliative Care; 2. Carcinoma, Non‐Small‐Cell Lung [mortality, *radiotherapy]; 3. Lung Neoplasms [mortality, *radiotherapy]; 4. Radiotherapy Dosage; 5. Randomized Controlled Trials as Topic;
MESH terms:
Dance/movement therapy for improving psychological and physical outcomes in cancer patients
1. Body Image; 2. Breast Neoplasms [*psychology, *rehabilitation]; 3. Dance Therapy [methods]; 4. Depression [*rehabilitation]; 5. Exercise Movement Techniques [*methods, psychology]; 6. Fatigue [*rehabilitation]; 7. Neoplasms [psychology, rehabilitation]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Self Concept; 11. Standard of Care;
MESH terms:
Follow‐up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test
1. Neoplasm Recurrence, Local [*diagnosis, virology]; 2. Neoplasm, Residual; 3. Papillomaviridae; 4. Papillomavirus Infections [*diagnosis]; 5. Uterine Cervical Dysplasia [*diagnosis, surgery]; 6. Uterine Cervical Neoplasms [*diagnosis, surgery, virology];
MESH terms:
Minimally invasive surgery versus open surgery for the treatment of solid abdominal and thoracic neoplasms in children
1. Abdominal Neoplasms [*surgery]; 2. Laparoscopy; 3. Laparotomy; 4. Thoracic Neoplasms [*surgery]; 5. Thoracoscopy; 6. Thoracotomy;
MESH terms:
Chemotherapy for children with medulloblastoma
1. Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; 2. Cerebellar Neoplasms [*drug therapy, mortality, radiotherapy]; 3. Disease‐Free Survival; 4. Medulloblastoma [*drug therapy, mortality, radiotherapy]; 5. Radiotherapy Dosage; 6. Randomized Controlled Trials as Topic;
MESH terms:
Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer
1. Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; 2. Chemoradiotherapy [*methods, mortality]; 3. Chemotherapy, Adjuvant [adverse effects, methods, mortality]; 4. Cisplatin [administration & dosage]; 5. Deoxycytidine [administration & dosage, analogs & derivatives]; 6. Fluorouracil [administration & dosage]; 7. Mitomycin [administration & dosage]; 8. Neoplasm Staging; 9. Randomized Controlled Trials as Topic; 10. Uterine Cervical Neoplasms [mortality, pathology, *therapy];
MESH terms:
Long‐term proton pump inhibitor (PPI) use and the development of gastric pre‐malignant lesions
1. Enterochromaffin‐like Cells [pathology]; 2. Gastritis, Atrophic [chemically induced]; 3. Hyperplasia [chemically induced]; 4. Intestines [pathology]; 5. Maintenance Chemotherapy [adverse effects]; 6. Metaplasia [chemically induced]; 7. Precancerous Conditions [*chemically induced, pathology]; 8. Proton Pump Inhibitors [*adverse effects]; 9. Randomized Controlled Trials as Topic; 10. Stomach Neoplasms [*chemically induced, pathology]; 11. Time Factors;
MESH terms:
Droperidol for treatment of nausea and vomiting in palliative care patients
1. Antiemetics [adverse effects, *therapeutic use]; 2. Droperidol [adverse effects, *therapeutic use]; 3. Nausea [*drug therapy]; 4. *Palliative Care; 5. Terminal Care; 6. Vomiting [*drug therapy];
MESH terms:
Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer
1. Adenocarcinoma [drug therapy, mortality, pathology]; 2. Antibodies, Monoclonal, Humanized [*therapeutic use]; 3. Antineoplastic Agents [*therapeutic use]; 4. Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; 5. Carcinoma, Non‐Small‐Cell Lung [*drug therapy, mortality, pathology]; 6. Cetuximab; 7. Disease‐Free Survival; 8. Lung Neoplasms [*drug therapy, mortality, pathology]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia
1. Anti-Bacterial Agents [therapeutic use]; 2. Chemotherapy-Induced Febrile Neutropenia [*drug therapy]; 3. Colony-Stimulating Factors [therapeutic use]; 4. Drug Therapy, Combination; 5. Fever [chemically induced, drug therapy]; 6. Granulocyte Colony-Stimulating Factor [*therapeutic use]; 7. Granulocyte-Macrophage Colony-Stimulating Factor [*therapeutic use]; 8. Neoplasms [drug therapy]; 9. Randomized Controlled Trials as Topic;
MESH terms:
High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer
1. Brachytherapy [*methods]; 2. Neoplasm Recurrence, Local; 3. Neoplasm Staging; 4. Radiotherapy Dosage; 5. Randomized Controlled Trials as Topic; 6. Uterine Cervical Neoplasms [mortality, pathology, *radiotherapy];
MESH terms:
Codeine, alone and with paracetamol (acetaminophen), for cancer pain
1. Acetaminophen [adverse effects, *therapeutic use]; 2. Analgesics, Non‐Narcotic [adverse effects, *therapeutic use]; 3. Analgesics, Opioid [adverse effects, *therapeutic use]; 4. Codeine [adverse effects, *therapeutic use]; 5. Drug Therapy, Combination [adverse effects, methods]; 6. Neoplasms [*complications]; 7. Pain [*drug therapy, etiology]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer
1. Anthracyclines [adverse effects, *therapeutic use]; 2. Antibiotics, Antineoplastic [adverse effects, *therapeutic use]; 3. Bone Neoplasms [drug therapy]; 4. Heart Diseases [chemically induced]; 5. Hepatoblastoma [drug therapy]; 6. Kidney Neoplasms [drug therapy]; 7. Leukemia, Myeloid, Acute [drug therapy]; 8. Liver Neoplasms [drug therapy]; 9. Lymphoma, Non‐Hodgkin [drug therapy]; 10. Neoplasms [*drug therapy]; 11. Precursor Cell Lymphoblastic Leukemia‐Lymphoma [drug therapy]; 12. Randomized Controlled Trials as Topic; 13. Sarcoma [drug therapy]; 14. Wilms Tumor [drug therapy];
MESH terms:
Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults
1. *Antiretroviral Therapy, Highly Active; 2. Alitretinoin; 3. Antineoplastic Agents [*therapeutic use]; 4. Bleomycin [administration & dosage]; 5. Doxorubicin [administration & dosage]; 6. Drug Therapy, Combination; 7. Etoposide [administration & dosage]; 8. HIV Infections [*complications, drug therapy]; 9. Liposomes; 10. Observational Studies as Topic; 11. Randomized Controlled Trials as Topic; 12. Sarcoma, Kaposi [*drug therapy, virology]; 13. Skin Neoplasms [*drug therapy, virology]; 14. Tretinoin [therapeutic use]; 15. Vincristine [administration & dosage];